nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—Bifonazole—Letrozole—breast cancer	0.251	0.436	CrCrCtD
Cyclizine—Cloperastine—Raloxifene—breast cancer	0.0632	0.11	CrCrCtD
Cyclizine—CYP2C9—Anastrozole—breast cancer	0.0576	0.332	CbGbCtD
Cyclizine—Phenoxybenzamine—Toremifene—breast cancer	0.0438	0.0761	CrCrCtD
Cyclizine—CYP2C9—Idarubicin—breast cancer	0.0437	0.252	CbGbCtD
Cyclizine—Orphenadrine—Toremifene—breast cancer	0.0306	0.0532	CrCrCtD
Cyclizine—Benzphetamine—Toremifene—breast cancer	0.0306	0.0532	CrCrCtD
Cyclizine—Benzyl Benzoate—Toremifene—breast cancer	0.0284	0.0493	CrCrCtD
Cyclizine—Phenoxybenzamine—Tamoxifen—breast cancer	0.0275	0.0478	CrCrCtD
Cyclizine—Diphenhydramine—Toremifene—breast cancer	0.0272	0.0473	CrCrCtD
Cyclizine—CYP2C9—Capecitabine—breast cancer	0.0239	0.138	CbGbCtD
Cyclizine—CYP2C9—Tamoxifen—breast cancer	0.0193	0.111	CbGbCtD
Cyclizine—Orphenadrine—Tamoxifen—breast cancer	0.0192	0.0334	CrCrCtD
Cyclizine—Benzphetamine—Tamoxifen—breast cancer	0.0192	0.0334	CrCrCtD
Cyclizine—Benzyl Benzoate—Tamoxifen—breast cancer	0.0178	0.031	CrCrCtD
Cyclizine—Diphenhydramine—Tamoxifen—breast cancer	0.0171	0.0297	CrCrCtD
Cyclizine—CYP2C9—Paclitaxel—breast cancer	0.015	0.0863	CbGbCtD
Cyclizine—CYP2C9—Fluorouracil—breast cancer	0.0142	0.0817	CbGbCtD
Cyclizine—SULT1E1—nipple—breast cancer	0.00515	0.225	CbGeAlD
Cyclizine—SULT1E1—female reproductive system—breast cancer	0.00257	0.113	CbGeAlD
Cyclizine—SULT1E1—adrenal gland—breast cancer	0.00251	0.11	CbGeAlD
Cyclizine—SULT1E1—female gonad—breast cancer	0.00234	0.103	CbGeAlD
Cyclizine—SULT1E1—endocrine gland—breast cancer	0.00218	0.0954	CbGeAlD
Cyclizine—SULT1E1—lymph node—breast cancer	0.00151	0.0659	CbGeAlD
Cyclizine—CYP2C9—mammary gland—breast cancer	0.00113	0.0494	CbGeAlD
Cyclizine—HRH1—nipple—breast cancer	0.00092	0.0403	CbGeAlD
Cyclizine—HRH1—epithelium—breast cancer	0.00062	0.0271	CbGeAlD
Cyclizine—HRH1—endometrium—breast cancer	0.000556	0.0243	CbGeAlD
Cyclizine—HRH1—adipose tissue—breast cancer	0.000501	0.0219	CbGeAlD
Cyclizine—CYP2C9—female reproductive system—breast cancer	0.000467	0.0204	CbGeAlD
Cyclizine—HRH1—female reproductive system—breast cancer	0.00046	0.0202	CbGeAlD
Cyclizine—HRH1—adrenal gland—breast cancer	0.000449	0.0197	CbGeAlD
Cyclizine—HRH1—female gonad—breast cancer	0.000419	0.0183	CbGeAlD
Cyclizine—CYP2C9—endocrine gland—breast cancer	0.000395	0.0173	CbGeAlD
Cyclizine—HRH1—endocrine gland—breast cancer	0.000389	0.0171	CbGeAlD
Cyclizine—Bifonazole—CYP17A1—breast cancer	0.000352	0.113	CrCbGaD
Cyclizine—HRH1—lymph node—breast cancer	0.000269	0.0118	CbGeAlD
Cyclizine—Trimethaphan—BCHE—breast cancer	0.000246	0.0792	CrCbGaD
Cyclizine—Bifonazole—CYP19A1—breast cancer	0.000179	0.0576	CrCbGaD
Cyclizine—Somnolence—Thiotepa—breast cancer	0.000155	0.00118	CcSEcCtD
Cyclizine—Hepatobiliary disease—Docetaxel—breast cancer	0.000155	0.00118	CcSEcCtD
Cyclizine—Hypersensitivity—Melphalan—breast cancer	0.000154	0.00117	CcSEcCtD
Cyclizine—Asthenia—Tamoxifen—breast cancer	0.000153	0.00117	CcSEcCtD
Cyclizine—Convulsion—Fluorouracil—breast cancer	0.000153	0.00117	CcSEcCtD
Cyclizine—Thrombophlebitis—Doxorubicin—breast cancer	0.000153	0.00116	CcSEcCtD
Cyclizine—Agranulocytosis—Docetaxel—breast cancer	0.000152	0.00116	CcSEcCtD
Cyclizine—Mental disorder—Paclitaxel—breast cancer	0.000152	0.00115	CcSEcCtD
Cyclizine—Hepatic function abnormal—Doxorubicin—breast cancer	0.000151	0.00115	CcSEcCtD
Cyclizine—Pruritus—Tamoxifen—breast cancer	0.000151	0.00115	CcSEcCtD
Cyclizine—Anaphylactic shock—Mitoxantrone—breast cancer	0.000151	0.00115	CcSEcCtD
Cyclizine—Anaphylactic shock—Irinotecan—breast cancer	0.000151	0.00115	CcSEcCtD
Cyclizine—Erythema—Paclitaxel—breast cancer	0.000151	0.00115	CcSEcCtD
Cyclizine—Hypersensitivity—Goserelin—breast cancer	0.00015	0.00114	CcSEcCtD
Cyclizine—Asthenia—Melphalan—breast cancer	0.00015	0.00114	CcSEcCtD
Cyclizine—Dermatitis bullous—Epirubicin—breast cancer	0.00015	0.00114	CcSEcCtD
Cyclizine—Hepatobiliary disease—Capecitabine—breast cancer	0.00015	0.00114	CcSEcCtD
Cyclizine—Pain—Thiotepa—breast cancer	0.000149	0.00114	CcSEcCtD
Cyclizine—Constipation—Thiotepa—breast cancer	0.000149	0.00114	CcSEcCtD
Cyclizine—Pruritus—Melphalan—breast cancer	0.000148	0.00113	CcSEcCtD
Cyclizine—Nervous system disorder—Irinotecan—breast cancer	0.000148	0.00112	CcSEcCtD
Cyclizine—Tension—Paclitaxel—breast cancer	0.000148	0.00112	CcSEcCtD
Cyclizine—Agranulocytosis—Capecitabine—breast cancer	0.000148	0.00112	CcSEcCtD
Cyclizine—Tachycardia—Mitoxantrone—breast cancer	0.000147	0.00112	CcSEcCtD
Cyclizine—Anaphylactic shock—Gemcitabine—breast cancer	0.000147	0.00112	CcSEcCtD
Cyclizine—Hepatitis—Docetaxel—breast cancer	0.000147	0.00112	CcSEcCtD
Cyclizine—Asthenia—Goserelin—breast cancer	0.000146	0.00111	CcSEcCtD
Cyclizine—Skin disorder—Mitoxantrone—breast cancer	0.000146	0.00111	CcSEcCtD
Cyclizine—Nervousness—Paclitaxel—breast cancer	0.000146	0.00111	CcSEcCtD
Cyclizine—Dizziness—Vinblastine—breast cancer	0.000145	0.00111	CcSEcCtD
Cyclizine—Urticaria—Vinorelbine—breast cancer	0.000145	0.0011	CcSEcCtD
Cyclizine—Muscle spasms—Paclitaxel—breast cancer	0.000145	0.0011	CcSEcCtD
Cyclizine—Pruritus—Goserelin—breast cancer	0.000144	0.0011	CcSEcCtD
Cyclizine—Anaphylactic shock—Fluorouracil—breast cancer	0.000144	0.0011	CcSEcCtD
Cyclizine—Connective tissue disorder—Docetaxel—breast cancer	0.000144	0.0011	CcSEcCtD
Cyclizine—Nervous system disorder—Gemcitabine—breast cancer	0.000144	0.0011	CcSEcCtD
Cyclizine—Skin disorder—Gemcitabine—breast cancer	0.000143	0.00108	CcSEcCtD
Cyclizine—Hepatitis—Capecitabine—breast cancer	0.000142	0.00108	CcSEcCtD
Cyclizine—Vision blurred—Paclitaxel—breast cancer	0.000142	0.00108	CcSEcCtD
Cyclizine—Nervous system disorder—Fluorouracil—breast cancer	0.000142	0.00108	CcSEcCtD
Cyclizine—Dizziness—Tamoxifen—breast cancer	0.000141	0.00107	CcSEcCtD
Cyclizine—Tremor—Paclitaxel—breast cancer	0.000141	0.00107	CcSEcCtD
Cyclizine—Tachycardia—Fluorouracil—breast cancer	0.000141	0.00107	CcSEcCtD
Cyclizine—Hypotension—Irinotecan—breast cancer	0.000141	0.00107	CcSEcCtD
Cyclizine—Hypotension—Mitoxantrone—breast cancer	0.000141	0.00107	CcSEcCtD
Cyclizine—Connective tissue disorder—Capecitabine—breast cancer	0.00014	0.00106	CcSEcCtD
Cyclizine—Urticaria—Thiotepa—breast cancer	0.000139	0.00105	CcSEcCtD
Cyclizine—Dermatitis bullous—Doxorubicin—breast cancer	0.000138	0.00105	CcSEcCtD
Cyclizine—Agitation—Paclitaxel—breast cancer	0.000138	0.00105	CcSEcCtD
Cyclizine—Headache—Vinblastine—breast cancer	0.000138	0.00105	CcSEcCtD
Cyclizine—Orphenadrine—SCN10A—breast cancer	0.000138	0.0444	CrCbGaD
Cyclizine—Angioedema—Paclitaxel—breast cancer	0.000138	0.00105	CcSEcCtD
Cyclizine—Reboxetine—CYP2D6—breast cancer	0.000138	0.0443	CrCbGaD
Cyclizine—Hypotension—Gemcitabine—breast cancer	0.000137	0.00104	CcSEcCtD
Cyclizine—Eye disorder—Docetaxel—breast cancer	0.000137	0.00104	CcSEcCtD
Cyclizine—Insomnia—Irinotecan—breast cancer	0.000136	0.00104	CcSEcCtD
Cyclizine—Paraesthesia—Irinotecan—breast cancer	0.000135	0.00103	CcSEcCtD
Cyclizine—Paraesthesia—Mitoxantrone—breast cancer	0.000135	0.00103	CcSEcCtD
Cyclizine—Dizziness—Goserelin—breast cancer	0.000135	0.00103	CcSEcCtD
Cyclizine—Hydroxyzine—CYP2D6—breast cancer	0.000135	0.0435	CrCbGaD
Cyclizine—Hypotension—Fluorouracil—breast cancer	0.000135	0.00103	CcSEcCtD
Cyclizine—Hypersensitivity—Vinorelbine—breast cancer	0.000135	0.00102	CcSEcCtD
Cyclizine—Somnolence—Irinotecan—breast cancer	0.000134	0.00102	CcSEcCtD
Cyclizine—Somnolence—Mitoxantrone—breast cancer	0.000134	0.00102	CcSEcCtD
Cyclizine—Headache—Tamoxifen—breast cancer	0.000134	0.00102	CcSEcCtD
Cyclizine—Insomnia—Gemcitabine—breast cancer	0.000133	0.00101	CcSEcCtD
Cyclizine—Eye disorder—Capecitabine—breast cancer	0.000133	0.00101	CcSEcCtD
Cyclizine—Paraesthesia—Gemcitabine—breast cancer	0.000132	0.001	CcSEcCtD
Cyclizine—Chills—Docetaxel—breast cancer	0.000132	0.001	CcSEcCtD
Cyclizine—Asthenia—Vinorelbine—breast cancer	0.000131	0.000997	CcSEcCtD
Cyclizine—Insomnia—Fluorouracil—breast cancer	0.000131	0.000993	CcSEcCtD
Cyclizine—Somnolence—Gemcitabine—breast cancer	0.000131	0.000993	CcSEcCtD
Cyclizine—Convulsion—Paclitaxel—breast cancer	0.000131	0.000993	CcSEcCtD
Cyclizine—Hypertension—Paclitaxel—breast cancer	0.00013	0.000989	CcSEcCtD
Cyclizine—Paraesthesia—Fluorouracil—breast cancer	0.00013	0.000986	CcSEcCtD
Cyclizine—Pruritus—Vinorelbine—breast cancer	0.000129	0.000983	CcSEcCtD
Cyclizine—Constipation—Mitoxantrone—breast cancer	0.000129	0.00098	CcSEcCtD
Cyclizine—Constipation—Irinotecan—breast cancer	0.000129	0.00098	CcSEcCtD
Cyclizine—Pain—Mitoxantrone—breast cancer	0.000129	0.00098	CcSEcCtD
Cyclizine—Pain—Irinotecan—breast cancer	0.000129	0.00098	CcSEcCtD
Cyclizine—Hypersensitivity—Thiotepa—breast cancer	0.000129	0.000978	CcSEcCtD
Cyclizine—Mental disorder—Docetaxel—breast cancer	0.000129	0.000977	CcSEcCtD
Cyclizine—Somnolence—Fluorouracil—breast cancer	0.000128	0.000976	CcSEcCtD
Cyclizine—Headache—Goserelin—breast cancer	0.000128	0.000972	CcSEcCtD
Cyclizine—Erythema—Docetaxel—breast cancer	0.000128	0.000971	CcSEcCtD
Cyclizine—Chills—Capecitabine—breast cancer	0.000127	0.000969	CcSEcCtD
Cyclizine—Pain—Gemcitabine—breast cancer	0.000126	0.000955	CcSEcCtD
Cyclizine—Constipation—Gemcitabine—breast cancer	0.000126	0.000955	CcSEcCtD
Cyclizine—Asthenia—Thiotepa—breast cancer	0.000125	0.000952	CcSEcCtD
Cyclizine—Mental disorder—Capecitabine—breast cancer	0.000124	0.000946	CcSEcCtD
Cyclizine—Erythema—Capecitabine—breast cancer	0.000124	0.00094	CcSEcCtD
Cyclizine—Pruritus—Thiotepa—breast cancer	0.000124	0.000939	CcSEcCtD
Cyclizine—Pain—Fluorouracil—breast cancer	0.000123	0.000939	CcSEcCtD
Cyclizine—Anaphylactic shock—Paclitaxel—breast cancer	0.000123	0.000935	CcSEcCtD
Cyclizine—Muscle spasms—Docetaxel—breast cancer	0.000123	0.000934	CcSEcCtD
Cyclizine—Dizziness—Vinorelbine—breast cancer	0.000121	0.000919	CcSEcCtD
Cyclizine—Nervous system disorder—Paclitaxel—breast cancer	0.000121	0.000917	CcSEcCtD
Cyclizine—Tachycardia—Paclitaxel—breast cancer	0.00012	0.000913	CcSEcCtD
Cyclizine—Urticaria—Mitoxantrone—breast cancer	0.00012	0.000911	CcSEcCtD
Cyclizine—Skin disorder—Paclitaxel—breast cancer	0.000119	0.000908	CcSEcCtD
Cyclizine—Muscle spasms—Capecitabine—breast cancer	0.000119	0.000904	CcSEcCtD
Cyclizine—Reboxetine—CYP3A4—breast cancer	0.000118	0.038	CrCbGaD
Cyclizine—Drowsiness—Methotrexate—breast cancer	0.000118	0.000896	CcSEcCtD
Cyclizine—Vision blurred—Capecitabine—breast cancer	0.000117	0.000886	CcSEcCtD
Cyclizine—Tremor—Capecitabine—breast cancer	0.000116	0.000881	CcSEcCtD
Cyclizine—Dizziness—Thiotepa—breast cancer	0.000115	0.000878	CcSEcCtD
Cyclizine—Hypotension—Paclitaxel—breast cancer	0.000115	0.000874	CcSEcCtD
Cyclizine—Urticaria—Fluorouracil—breast cancer	0.000115	0.000872	CcSEcCtD
Cyclizine—Headache—Vinorelbine—breast cancer	0.000115	0.000871	CcSEcCtD
Cyclizine—Hepatobiliary disease—Methotrexate—breast cancer	0.000111	0.000847	CcSEcCtD
Cyclizine—Insomnia—Paclitaxel—breast cancer	0.000111	0.000846	CcSEcCtD
Cyclizine—Hypersensitivity—Mitoxantrone—breast cancer	0.000111	0.000845	CcSEcCtD
Cyclizine—Hypersensitivity—Irinotecan—breast cancer	0.000111	0.000845	CcSEcCtD
Cyclizine—Convulsion—Docetaxel—breast cancer	0.000111	0.000841	CcSEcCtD
Cyclizine—Paraesthesia—Paclitaxel—breast cancer	0.00011	0.00084	CcSEcCtD
Cyclizine—Hypertension—Docetaxel—breast cancer	0.00011	0.000838	CcSEcCtD
Cyclizine—Drowsiness—Epirubicin—breast cancer	0.00011	0.000838	CcSEcCtD
Cyclizine—Agranulocytosis—Methotrexate—breast cancer	0.00011	0.000836	CcSEcCtD
Cyclizine—Headache—Thiotepa—breast cancer	0.000109	0.000832	CcSEcCtD
Cyclizine—Somnolence—Paclitaxel—breast cancer	0.000109	0.000831	CcSEcCtD
Cyclizine—Asthenia—Mitoxantrone—breast cancer	0.000108	0.000823	CcSEcCtD
Cyclizine—Asthenia—Irinotecan—breast cancer	0.000108	0.000823	CcSEcCtD
Cyclizine—Hypertension—Capecitabine—breast cancer	0.000107	0.000812	CcSEcCtD
Cyclizine—Hypersensitivity—Fluorouracil—breast cancer	0.000106	0.000809	CcSEcCtD
Cyclizine—Flunarizine—CYP1A1—breast cancer	0.000106	0.0341	CrCbGaD
Cyclizine—Hepatitis—Methotrexate—breast cancer	0.000106	0.000804	CcSEcCtD
Cyclizine—Asthenia—Gemcitabine—breast cancer	0.000105	0.000801	CcSEcCtD
Cyclizine—Pain—Paclitaxel—breast cancer	0.000105	0.0008	CcSEcCtD
Cyclizine—Constipation—Paclitaxel—breast cancer	0.000105	0.0008	CcSEcCtD
Cyclizine—Hepatobiliary disease—Epirubicin—breast cancer	0.000104	0.000793	CcSEcCtD
Cyclizine—Anaphylactic shock—Docetaxel—breast cancer	0.000104	0.000792	CcSEcCtD
Cyclizine—Pruritus—Gemcitabine—breast cancer	0.000104	0.00079	CcSEcCtD
Cyclizine—Agranulocytosis—Epirubicin—breast cancer	0.000103	0.000782	CcSEcCtD
Cyclizine—Nervous system disorder—Docetaxel—breast cancer	0.000102	0.000777	CcSEcCtD
Cyclizine—Pruritus—Fluorouracil—breast cancer	0.000102	0.000777	CcSEcCtD
Cyclizine—Drowsiness—Doxorubicin—breast cancer	0.000102	0.000775	CcSEcCtD
Cyclizine—Tachycardia—Docetaxel—breast cancer	0.000102	0.000773	CcSEcCtD
Cyclizine—Skin disorder—Docetaxel—breast cancer	0.000101	0.00077	CcSEcCtD
Cyclizine—Dizziness—Irinotecan—breast cancer	9.97e-05	0.000758	CcSEcCtD
Cyclizine—Nervous system disorder—Capecitabine—breast cancer	9.9e-05	0.000752	CcSEcCtD
Cyclizine—Hepatitis—Epirubicin—breast cancer	9.89e-05	0.000752	CcSEcCtD
Cyclizine—Eye disorder—Methotrexate—breast cancer	9.88e-05	0.000751	CcSEcCtD
Cyclizine—Tachycardia—Capecitabine—breast cancer	9.85e-05	0.000749	CcSEcCtD
Cyclizine—Reboxetine—ABCB1—breast cancer	9.82e-05	0.0316	CrCbGaD
Cyclizine—Skin disorder—Capecitabine—breast cancer	9.8e-05	0.000745	CcSEcCtD
Cyclizine—Urticaria—Paclitaxel—breast cancer	9.77e-05	0.000743	CcSEcCtD
Cyclizine—Hypotension—Docetaxel—breast cancer	9.74e-05	0.000741	CcSEcCtD
Cyclizine—Connective tissue disorder—Epirubicin—breast cancer	9.72e-05	0.000739	CcSEcCtD
Cyclizine—Hepatobiliary disease—Doxorubicin—breast cancer	9.65e-05	0.000733	CcSEcCtD
Cyclizine—Dizziness—Fluorouracil—breast cancer	9.55e-05	0.000726	CcSEcCtD
Cyclizine—Agranulocytosis—Doxorubicin—breast cancer	9.52e-05	0.000724	CcSEcCtD
Cyclizine—Chills—Methotrexate—breast cancer	9.49e-05	0.000721	CcSEcCtD
Cyclizine—Headache—Mitoxantrone—breast cancer	9.44e-05	0.000718	CcSEcCtD
Cyclizine—Headache—Irinotecan—breast cancer	9.44e-05	0.000718	CcSEcCtD
Cyclizine—Hypotension—Capecitabine—breast cancer	9.43e-05	0.000717	CcSEcCtD
Cyclizine—Insomnia—Docetaxel—breast cancer	9.43e-05	0.000717	CcSEcCtD
Cyclizine—Paraesthesia—Docetaxel—breast cancer	9.36e-05	0.000712	CcSEcCtD
Cyclizine—Somnolence—Docetaxel—breast cancer	9.27e-05	0.000705	CcSEcCtD
Cyclizine—Mental disorder—Methotrexate—breast cancer	9.26e-05	0.000704	CcSEcCtD
Cyclizine—Eye disorder—Epirubicin—breast cancer	9.25e-05	0.000703	CcSEcCtD
Cyclizine—Erythema—Methotrexate—breast cancer	9.2e-05	0.0007	CcSEcCtD
Cyclizine—Headache—Gemcitabine—breast cancer	9.2e-05	0.0007	CcSEcCtD
Cyclizine—Hepatitis—Doxorubicin—breast cancer	9.16e-05	0.000696	CcSEcCtD
Cyclizine—Insomnia—Capecitabine—breast cancer	9.13e-05	0.000694	CcSEcCtD
Cyclizine—Paraesthesia—Capecitabine—breast cancer	9.06e-05	0.000689	CcSEcCtD
Cyclizine—Hypersensitivity—Paclitaxel—breast cancer	9.06e-05	0.000689	CcSEcCtD
Cyclizine—Headache—Fluorouracil—breast cancer	9.05e-05	0.000688	CcSEcCtD
Cyclizine—Connective tissue disorder—Doxorubicin—breast cancer	9e-05	0.000684	CcSEcCtD
Cyclizine—Clozapine—CYP1B1—breast cancer	8.98e-05	0.0289	CrCbGaD
Cyclizine—Constipation—Docetaxel—breast cancer	8.91e-05	0.000678	CcSEcCtD
Cyclizine—Pain—Docetaxel—breast cancer	8.91e-05	0.000678	CcSEcCtD
Cyclizine—Chills—Epirubicin—breast cancer	8.88e-05	0.000675	CcSEcCtD
Cyclizine—Asthenia—Paclitaxel—breast cancer	8.82e-05	0.000671	CcSEcCtD
Cyclizine—Pruritus—Paclitaxel—breast cancer	8.7e-05	0.000661	CcSEcCtD
Cyclizine—Benzatropine—CYP2D6—breast cancer	8.7e-05	0.028	CrCbGaD
Cyclizine—Vision blurred—Methotrexate—breast cancer	8.67e-05	0.00066	CcSEcCtD
Cyclizine—Mental disorder—Epirubicin—breast cancer	8.67e-05	0.000659	CcSEcCtD
Cyclizine—Pain—Capecitabine—breast cancer	8.63e-05	0.000656	CcSEcCtD
Cyclizine—Constipation—Capecitabine—breast cancer	8.63e-05	0.000656	CcSEcCtD
Cyclizine—Erythema—Epirubicin—breast cancer	8.61e-05	0.000655	CcSEcCtD
Cyclizine—Eye disorder—Doxorubicin—breast cancer	8.56e-05	0.000651	CcSEcCtD
Cyclizine—Tension—Epirubicin—breast cancer	8.45e-05	0.000643	CcSEcCtD
Cyclizine—Bifonazole—CYP3A4—breast cancer	8.4e-05	0.0271	CrCbGaD
Cyclizine—Cinnarizine—CYP1A1—breast cancer	8.37e-05	0.027	CrCbGaD
Cyclizine—Nervousness—Epirubicin—breast cancer	8.37e-05	0.000636	CcSEcCtD
Cyclizine—Muscle spasms—Epirubicin—breast cancer	8.28e-05	0.00063	CcSEcCtD
Cyclizine—Chills—Doxorubicin—breast cancer	8.21e-05	0.000625	CcSEcCtD
Cyclizine—Dizziness—Paclitaxel—breast cancer	8.13e-05	0.000618	CcSEcCtD
Cyclizine—Vision blurred—Epirubicin—breast cancer	8.12e-05	0.000617	CcSEcCtD
Cyclizine—Mental disorder—Doxorubicin—breast cancer	8.02e-05	0.00061	CcSEcCtD
Cyclizine—Urticaria—Capecitabine—breast cancer	8.02e-05	0.00061	CcSEcCtD
Cyclizine—Convulsion—Methotrexate—breast cancer	7.97e-05	0.000606	CcSEcCtD
Cyclizine—Erythema—Doxorubicin—breast cancer	7.97e-05	0.000606	CcSEcCtD
Cyclizine—Agitation—Epirubicin—breast cancer	7.92e-05	0.000602	CcSEcCtD
Cyclizine—Flunarizine—CYP2D6—breast cancer	7.88e-05	0.0254	CrCbGaD
Cyclizine—Tension—Doxorubicin—breast cancer	7.82e-05	0.000595	CcSEcCtD
Cyclizine—Nervousness—Doxorubicin—breast cancer	7.74e-05	0.000589	CcSEcCtD
Cyclizine—Headache—Paclitaxel—breast cancer	7.7e-05	0.000586	CcSEcCtD
Cyclizine—Hypersensitivity—Docetaxel—breast cancer	7.68e-05	0.000584	CcSEcCtD
Cyclizine—Muscle spasms—Doxorubicin—breast cancer	7.66e-05	0.000583	CcSEcCtD
Cyclizine—Phenprocoumon—CYP3A4—breast cancer	7.6e-05	0.0245	CrCbGaD
Cyclizine—Anaphylactic shock—Methotrexate—breast cancer	7.51e-05	0.000571	CcSEcCtD
Cyclizine—Vision blurred—Doxorubicin—breast cancer	7.51e-05	0.000571	CcSEcCtD
Cyclizine—Asthenia—Docetaxel—breast cancer	7.48e-05	0.000569	CcSEcCtD
Cyclizine—Convulsion—Epirubicin—breast cancer	7.46e-05	0.000567	CcSEcCtD
Cyclizine—Hypertension—Epirubicin—breast cancer	7.44e-05	0.000565	CcSEcCtD
Cyclizine—Hypersensitivity—Capecitabine—breast cancer	7.43e-05	0.000565	CcSEcCtD
Cyclizine—Pruritus—Docetaxel—breast cancer	7.37e-05	0.000561	CcSEcCtD
Cyclizine—Nervous system disorder—Methotrexate—breast cancer	7.37e-05	0.00056	CcSEcCtD
Cyclizine—Agitation—Doxorubicin—breast cancer	7.32e-05	0.000557	CcSEcCtD
Cyclizine—Skin disorder—Methotrexate—breast cancer	7.3e-05	0.000555	CcSEcCtD
Cyclizine—Asthenia—Capecitabine—breast cancer	7.24e-05	0.000551	CcSEcCtD
Cyclizine—Pruritus—Capecitabine—breast cancer	7.14e-05	0.000543	CcSEcCtD
Cyclizine—Anaphylactic shock—Epirubicin—breast cancer	7.03e-05	0.000535	CcSEcCtD
Cyclizine—Hypotension—Methotrexate—breast cancer	7.02e-05	0.000534	CcSEcCtD
Cyclizine—Convulsion—Doxorubicin—breast cancer	6.91e-05	0.000525	CcSEcCtD
Cyclizine—Nervous system disorder—Epirubicin—breast cancer	6.89e-05	0.000524	CcSEcCtD
Cyclizine—Dizziness—Docetaxel—breast cancer	6.89e-05	0.000524	CcSEcCtD
Cyclizine—Hypertension—Doxorubicin—breast cancer	6.88e-05	0.000523	CcSEcCtD
Cyclizine—Tachycardia—Epirubicin—breast cancer	6.86e-05	0.000522	CcSEcCtD
Cyclizine—Bepridil—CYP2D6—breast cancer	6.85e-05	0.0221	CrCbGaD
Cyclizine—Skin disorder—Epirubicin—breast cancer	6.83e-05	0.000519	CcSEcCtD
Cyclizine—Insomnia—Methotrexate—breast cancer	6.79e-05	0.000517	CcSEcCtD
Cyclizine—Paraesthesia—Methotrexate—breast cancer	6.75e-05	0.000513	CcSEcCtD
Cyclizine—Somnolence—Methotrexate—breast cancer	6.68e-05	0.000508	CcSEcCtD
Cyclizine—Dizziness—Capecitabine—breast cancer	6.67e-05	0.000507	CcSEcCtD
Cyclizine—Phenprocoumon—ALB—breast cancer	6.63e-05	0.0214	CrCbGaD
Cyclizine—Diphenhydramine—PTGS1—breast cancer	6.57e-05	0.0212	CrCbGaD
Cyclizine—Hypotension—Epirubicin—breast cancer	6.57e-05	0.000499	CcSEcCtD
Cyclizine—Headache—Docetaxel—breast cancer	6.53e-05	0.000496	CcSEcCtD
Cyclizine—Anaphylactic shock—Doxorubicin—breast cancer	6.5e-05	0.000495	CcSEcCtD
Cyclizine—Pain—Methotrexate—breast cancer	6.42e-05	0.000488	CcSEcCtD
Cyclizine—Nervous system disorder—Doxorubicin—breast cancer	6.38e-05	0.000485	CcSEcCtD
Cyclizine—Insomnia—Epirubicin—breast cancer	6.36e-05	0.000483	CcSEcCtD
Cyclizine—Tachycardia—Doxorubicin—breast cancer	6.35e-05	0.000483	CcSEcCtD
Cyclizine—Headache—Capecitabine—breast cancer	6.32e-05	0.000481	CcSEcCtD
Cyclizine—Skin disorder—Doxorubicin—breast cancer	6.32e-05	0.00048	CcSEcCtD
Cyclizine—Paraesthesia—Epirubicin—breast cancer	6.31e-05	0.00048	CcSEcCtD
Cyclizine—Somnolence—Epirubicin—breast cancer	6.25e-05	0.000475	CcSEcCtD
Cyclizine—Cinnarizine—CYP2D6—breast cancer	6.23e-05	0.0201	CrCbGaD
Cyclizine—Hypotension—Doxorubicin—breast cancer	6.08e-05	0.000462	CcSEcCtD
Cyclizine—Constipation—Epirubicin—breast cancer	6.01e-05	0.000457	CcSEcCtD
Cyclizine—Pain—Epirubicin—breast cancer	6.01e-05	0.000457	CcSEcCtD
Cyclizine—Prochlorperazine—CYP2D6—breast cancer	5.99e-05	0.0193	CrCbGaD
Cyclizine—Urticaria—Methotrexate—breast cancer	5.97e-05	0.000454	CcSEcCtD
Cyclizine—Insomnia—Doxorubicin—breast cancer	5.88e-05	0.000447	CcSEcCtD
Cyclizine—Paraesthesia—Doxorubicin—breast cancer	5.84e-05	0.000444	CcSEcCtD
Cyclizine—Somnolence—Doxorubicin—breast cancer	5.78e-05	0.00044	CcSEcCtD
Cyclizine—Urticaria—Epirubicin—breast cancer	5.58e-05	0.000425	CcSEcCtD
Cyclizine—Pain—Doxorubicin—breast cancer	5.56e-05	0.000423	CcSEcCtD
Cyclizine—Constipation—Doxorubicin—breast cancer	5.56e-05	0.000423	CcSEcCtD
Cyclizine—Atomoxetine—CYP2D6—breast cancer	5.54e-05	0.0178	CrCbGaD
Cyclizine—Hypersensitivity—Methotrexate—breast cancer	5.53e-05	0.000421	CcSEcCtD
Cyclizine—Modafinil—CYP3A4—breast cancer	5.52e-05	0.0178	CrCbGaD
Cyclizine—Mianserin—CYP2D6—breast cancer	5.41e-05	0.0174	CrCbGaD
Cyclizine—Fentanyl—CYP3A4—breast cancer	5.4e-05	0.0174	CrCbGaD
Cyclizine—Asthenia—Methotrexate—breast cancer	5.39e-05	0.00041	CcSEcCtD
Cyclizine—Pruritus—Methotrexate—breast cancer	5.31e-05	0.000404	CcSEcCtD
Cyclizine—Hypersensitivity—Epirubicin—breast cancer	5.18e-05	0.000394	CcSEcCtD
Cyclizine—Urticaria—Doxorubicin—breast cancer	5.17e-05	0.000393	CcSEcCtD
Cyclizine—Prochlorperazine—CYP3A4—breast cancer	5.13e-05	0.0165	CrCbGaD
Cyclizine—Asthenia—Epirubicin—breast cancer	5.04e-05	0.000384	CcSEcCtD
Cyclizine—Pruritus—Epirubicin—breast cancer	4.97e-05	0.000378	CcSEcCtD
Cyclizine—Dizziness—Methotrexate—breast cancer	4.97e-05	0.000378	CcSEcCtD
Cyclizine—Bepridil—ABCB1—breast cancer	4.89e-05	0.0158	CrCbGaD
Cyclizine—Clozapine—CYP1A1—breast cancer	4.85e-05	0.0156	CrCbGaD
Cyclizine—Hypersensitivity—Doxorubicin—breast cancer	4.79e-05	0.000364	CcSEcCtD
Cyclizine—Benzphetamine—CYP3A4—breast cancer	4.79e-05	0.0154	CrCbGaD
Cyclizine—Atomoxetine—CYP3A4—breast cancer	4.75e-05	0.0153	CrCbGaD
Cyclizine—Headache—Methotrexate—breast cancer	4.71e-05	0.000358	CcSEcCtD
Cyclizine—Asthenia—Doxorubicin—breast cancer	4.67e-05	0.000355	CcSEcCtD
Cyclizine—Dizziness—Epirubicin—breast cancer	4.65e-05	0.000353	CcSEcCtD
Cyclizine—Mianserin—CYP3A4—breast cancer	4.64e-05	0.015	CrCbGaD
Cyclizine—Pruritus—Doxorubicin—breast cancer	4.6e-05	0.00035	CcSEcCtD
Cyclizine—Phenoxybenzamine—CYP3A4—breast cancer	4.58e-05	0.0147	CrCbGaD
Cyclizine—Fentanyl—ABCB1—breast cancer	4.5e-05	0.0145	CrCbGaD
Cyclizine—Diphenhydramine—CYP2D6—breast cancer	4.47e-05	0.0144	CrCbGaD
Cyclizine—Headache—Epirubicin—breast cancer	4.4e-05	0.000335	CcSEcCtD
Cyclizine—Dizziness—Doxorubicin—breast cancer	4.3e-05	0.000327	CcSEcCtD
Cyclizine—Headache—Doxorubicin—breast cancer	4.07e-05	0.00031	CcSEcCtD
Cyclizine—Orphenadrine—CYP3A4—breast cancer	3.63e-05	0.0117	CrCbGaD
Cyclizine—Clozapine—CYP2D6—breast cancer	3.61e-05	0.0116	CrCbGaD
Cyclizine—Clozapine—CYP3A4—breast cancer	3.1e-05	0.00998	CrCbGaD
Cyclizine—Clozapine—ABCB1—breast cancer	2.58e-05	0.0083	CrCbGaD
Cyclizine—CYP2C9—Metabolism—APRT—breast cancer	1.64e-05	0.000176	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—breast cancer	1.64e-05	0.000176	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ARHGDIA—breast cancer	1.62e-05	0.000173	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—FASN—breast cancer	1.61e-05	0.000173	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—breast cancer	1.61e-05	0.000172	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FST—breast cancer	1.58e-05	0.000169	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HEY2—breast cancer	1.56e-05	0.000167	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ESRRA—breast cancer	1.55e-05	0.000165	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ANGPTL4—breast cancer	1.55e-05	0.000165	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RPS6KB2—breast cancer	1.54e-05	0.000165	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RGS2—breast cancer	1.52e-05	0.000163	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—breast cancer	1.51e-05	0.000161	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCL20—breast cancer	1.5e-05	0.000161	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AGTR1—breast cancer	1.5e-05	0.000161	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—ITPR1—breast cancer	1.48e-05	0.000159	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—breast cancer	1.47e-05	0.000157	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HADHB—breast cancer	1.47e-05	0.000157	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GPI—breast cancer	1.47e-05	0.000157	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LPAR1—breast cancer	1.46e-05	0.000156	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TLE3—breast cancer	1.46e-05	0.000156	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HEY1—breast cancer	1.44e-05	0.000154	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—DLL1—breast cancer	1.41e-05	0.000151	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—breast cancer	1.4e-05	0.00015	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALDH7A1—breast cancer	1.4e-05	0.00015	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALDH1A1—breast cancer	1.4e-05	0.00015	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	1.39e-05	0.000149	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIST1H2BK—breast cancer	1.39e-05	0.000149	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIST1H2BC—breast cancer	1.39e-05	0.000149	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—breast cancer	1.38e-05	0.000148	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GRB7—breast cancer	1.38e-05	0.000147	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PDE4D—breast cancer	1.38e-05	0.000147	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—AKT1—breast cancer	1.38e-05	0.000147	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CSF2—breast cancer	1.37e-05	0.000147	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TAB2—breast cancer	1.35e-05	0.000145	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—ITPR1—breast cancer	1.35e-05	0.000144	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CNR2—breast cancer	1.34e-05	0.000144	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—FHL2—breast cancer	1.34e-05	0.000143	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NME1—breast cancer	1.34e-05	0.000143	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PHGDH—breast cancer	1.34e-05	0.000143	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ADSL—breast cancer	1.34e-05	0.000143	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—UMPS—breast cancer	1.34e-05	0.000143	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CXCL8—breast cancer	1.34e-05	0.000143	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—MMP3—breast cancer	1.34e-05	0.000143	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	1.34e-05	0.000143	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—BRIP1—breast cancer	1.31e-05	0.000141	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—LDHB—breast cancer	1.31e-05	0.000141	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HPSE—breast cancer	1.31e-05	0.000141	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—DKK1—breast cancer	1.31e-05	0.00014	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VEGFC—breast cancer	1.3e-05	0.000139	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JAG2—breast cancer	1.28e-05	0.000137	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—WNT1—breast cancer	1.26e-05	0.000135	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PLA2G4A—breast cancer	1.26e-05	0.000135	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA3—breast cancer	1.25e-05	0.000133	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCC1—breast cancer	1.25e-05	0.000133	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HMMR—breast cancer	1.25e-05	0.000133	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CSF2—breast cancer	1.24e-05	0.000133	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PPARGC1B—breast cancer	1.21e-05	0.000129	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOTCH4—breast cancer	1.2e-05	0.000128	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GZMB—breast cancer	1.19e-05	0.000127	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	1.18e-05	0.000126	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	1.18e-05	0.000126	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AGTR2—breast cancer	1.15e-05	0.000123	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCL2—breast cancer	1.15e-05	0.000123	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—BMP2—breast cancer	1.14e-05	0.000122	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PTHLH—breast cancer	1.14e-05	0.000122	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA4—breast cancer	1.14e-05	0.000122	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CA9—breast cancer	1.14e-05	0.000122	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—breast cancer	1.13e-05	0.00012	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	1.11e-05	0.000119	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GPX2—breast cancer	1.11e-05	0.000119	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA2—breast cancer	1.11e-05	0.000119	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EDNRB—breast cancer	1.1e-05	0.000118	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SULT1A1—breast cancer	1.1e-05	0.000117	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GPX4—breast cancer	1.1e-05	0.000117	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PGR—breast cancer	1.09e-05	0.000117	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—THBS1—breast cancer	1.09e-05	0.000116	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA1—breast cancer	1.07e-05	0.000115	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—IDH1—breast cancer	1.07e-05	0.000115	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NAT2—breast cancer	1.06e-05	0.000113	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FLT1—breast cancer	1.04e-05	0.000111	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SQSTM1—breast cancer	1.03e-05	0.000111	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGF3—breast cancer	1.03e-05	0.000111	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CG—breast cancer	1.03e-05	0.00011	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JAG1—breast cancer	1.02e-05	0.000109	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOTCH3—breast cancer	1.02e-05	0.000109	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PARP1—breast cancer	1.02e-05	0.000109	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CALCA—breast cancer	1e-05	0.000107	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RPS6—breast cancer	9.92e-06	0.000106	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGF4—breast cancer	9.84e-06	0.000105	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCR4—breast cancer	9.81e-06	0.000105	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCL12—breast cancer	9.81e-06	0.000105	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PAK1—breast cancer	9.62e-06	0.000103	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—breast cancer	9.58e-06	0.000103	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TCF7L2—breast cancer	9.45e-06	0.000101	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—AKT2—breast cancer	9.41e-06	0.000101	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CG—breast cancer	9.34e-06	0.0001	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MED12—breast cancer	9.29e-06	9.95e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—DPYD—breast cancer	9.29e-06	9.95e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALDOA—breast cancer	9.15e-06	9.79e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HSP90AA1—breast cancer	9.12e-06	9.76e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOTCH2—breast cancer	9.12e-06	9.76e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CD—breast cancer	9.04e-06	9.68e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NCOA3—breast cancer	8.88e-06	9.5e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PRL—breast cancer	8.87e-06	9.49e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AGTR1—breast cancer	8.87e-06	9.49e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC2A2—breast cancer	8.82e-06	9.44e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ADAM10—breast cancer	8.74e-06	9.35e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—STK11—breast cancer	8.74e-06	9.35e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	8.73e-06	9.34e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PLG—breast cancer	8.64e-06	9.25e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCG2—breast cancer	8.64e-06	9.25e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CPT1A—breast cancer	8.64e-06	9.25e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MTR—breast cancer	8.64e-06	9.25e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AKT2—breast cancer	8.55e-06	9.15e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGF10—breast cancer	8.5e-06	9.1e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HPGDS—breast cancer	8.47e-06	9.07e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HBA1—breast cancer	8.42e-06	9.01e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ACHE—breast cancer	8.22e-06	8.79e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTT1—breast cancer	8.22e-06	8.79e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CD—breast cancer	8.21e-06	8.79e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PDGFA—breast cancer	8.2e-06	8.78e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFBR2—breast cancer	8.09e-06	8.65e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ITPR1—breast cancer	7.96e-06	8.52e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—STAT5A—breast cancer	7.9e-06	8.46e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ERBB4—breast cancer	7.9e-06	8.46e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MMP3—breast cancer	7.9e-06	8.46e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CB—breast cancer	7.88e-06	8.43e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP17A1—breast cancer	7.78e-06	8.32e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ENO1—breast cancer	7.7e-06	8.24e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS1—breast cancer	7.7e-06	8.24e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	7.67e-06	8.21e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SMAD4—breast cancer	7.65e-06	8.19e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF1R—breast cancer	7.61e-06	8.14e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CXCL8—breast cancer	7.57e-06	8.11e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	7.57e-06	8.11e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP2D6—breast cancer	7.55e-06	8.08e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HES1—breast cancer	7.47e-06	8e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NCOR1—breast cancer	7.43e-06	7.95e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PLA2G4A—breast cancer	7.43e-06	7.95e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NCOA2—breast cancer	7.41e-06	7.93e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGF1—breast cancer	7.35e-06	7.86e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CSF2—breast cancer	7.35e-06	7.86e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—RAF1—breast cancer	7.33e-06	7.85e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NRG1—breast cancer	7.29e-06	7.81e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—H2AFX—breast cancer	7.24e-06	7.75e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—IL2—breast cancer	7.24e-06	7.75e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—E2F1—breast cancer	7.19e-06	7.7e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—FASN—breast cancer	7.19e-06	7.69e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—BCHE—breast cancer	7.16e-06	7.66e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CB—breast cancer	7.16e-06	7.66e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC5A5—breast cancer	7.07e-06	7.57e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SPP1—breast cancer	6.91e-06	7.39e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CXCL8—breast cancer	6.88e-06	7.36e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ERBB3—breast cancer	6.83e-06	7.31e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NQO1—breast cancer	6.83e-06	7.31e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC2A1—breast cancer	6.83e-06	7.31e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGFR2—breast cancer	6.82e-06	7.3e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	6.69e-06	7.16e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP3A4—breast cancer	6.66e-06	7.13e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	6.63e-06	7.09e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL2—breast cancer	6.57e-06	7.03e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TERT—breast cancer	6.55e-06	7.01e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP1B1—breast cancer	6.55e-06	7.01e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HSP90AA1—breast cancer	6.42e-06	6.87e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGFR1—breast cancer	6.36e-06	6.81e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HIF1A—breast cancer	6.26e-06	6.7e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NCOA1—breast cancer	6.25e-06	6.68e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—STK11—breast cancer	6.16e-06	6.59e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP19A1—breast cancer	6.16e-06	6.59e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—LEP—breast cancer	6.11e-06	6.54e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CAV1—breast cancer	6.06e-06	6.48e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KDR—breast cancer	5.99e-06	6.41e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ESR1—breast cancer	5.84e-06	6.25e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	5.78e-06	6.18e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FN1—breast cancer	5.77e-06	6.17e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—COMT—breast cancer	5.72e-06	6.12e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NFKBIA—breast cancer	5.7e-06	6.1e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTP1—breast cancer	5.7e-06	6.1e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOTCH1—breast cancer	5.64e-06	6.04e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HMOX1—breast cancer	5.62e-06	6.01e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ITPR1—breast cancer	5.6e-06	6e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APC—breast cancer	5.52e-06	5.91e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CG—breast cancer	5.52e-06	5.91e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KIT—breast cancer	5.52e-06	5.91e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EGF—breast cancer	5.45e-06	5.84e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ABCB1—breast cancer	5.39e-06	5.77e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—TYMS—breast cancer	5.3e-06	5.67e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—MAPK3—breast cancer	5.28e-06	5.66e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTM1—breast cancer	5.23e-06	5.6e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PLA2G4A—breast cancer	5.23e-06	5.6e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NCOR1—breast cancer	5.23e-06	5.6e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—BRAF—breast cancer	5.19e-06	5.55e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF1—breast cancer	5.05e-06	5.41e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AKT2—breast cancer	5.05e-06	5.4e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—EGFR—breast cancer	5.03e-06	5.38e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GPX1—breast cancer	5.01e-06	5.36e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP1A1—breast cancer	4.96e-06	5.31e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ERCC2—breast cancer	4.92e-06	5.27e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CD—breast cancer	4.85e-06	5.19e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CA—breast cancer	4.8e-06	5.14e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SERPINE1—breast cancer	4.8e-06	5.13e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—KRAS—breast cancer	4.75e-06	5.08e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MTHFR—breast cancer	4.63e-06	4.95e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NOS3—breast cancer	4.58e-06	4.9e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CA—breast cancer	4.36e-06	4.67e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MDM2—breast cancer	4.35e-06	4.65e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RAF1—breast cancer	4.33e-06	4.63e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RELA—breast cancer	4.31e-06	4.61e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ERBB2—breast cancer	4.28e-06	4.59e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CAV1—breast cancer	4.27e-06	4.57e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MTOR—breast cancer	4.23e-06	4.52e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CB—breast cancer	4.23e-06	4.52e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	4.08e-06	4.36e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCL8—breast cancer	4.06e-06	4.35e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—HRAS—breast cancer	4.04e-06	4.32e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1B—breast cancer	3.97e-06	4.25e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—AKT1—breast cancer	3.92e-06	4.2e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CASP3—breast cancer	3.89e-06	4.16e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CG—breast cancer	3.89e-06	4.16e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL2—breast cancer	3.88e-06	4.16e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL6—breast cancer	3.86e-06	4.13e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCND1—breast cancer	3.79e-06	4.05e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JUN—breast cancer	3.78e-06	4.04e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CTNNB1—breast cancer	3.75e-06	4.01e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MMP9—breast cancer	3.67e-06	3.93e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1A—breast cancer	3.66e-06	3.92e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PTEN—breast cancer	3.65e-06	3.91e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAPK8—breast cancer	3.57e-06	3.82e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AKT1—breast cancer	3.56e-06	3.81e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CD—breast cancer	3.42e-06	3.66e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SRC—breast cancer	3.39e-06	3.63e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALB—breast cancer	3.37e-06	3.61e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VEGFA—breast cancer	3.3e-06	3.53e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—STAT3—breast cancer	3.27e-06	3.5e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NOS3—breast cancer	3.23e-06	3.45e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAPK3—breast cancer	3.12e-06	3.34e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MYC—breast cancer	3.04e-06	3.25e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFB1—breast cancer	3.03e-06	3.24e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CB—breast cancer	2.98e-06	3.19e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EGFR—breast cancer	2.97e-06	3.18e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS2—breast cancer	2.95e-06	3.16e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KRAS—breast cancer	2.81e-06	3e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CA—breast cancer	2.58e-06	2.76e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTEN—breast cancer	2.57e-06	2.75e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TP53—breast cancer	2.49e-06	2.67e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HRAS—breast cancer	2.38e-06	2.55e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL6—breast cancer	2.28e-06	2.44e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AKT1—breast cancer	2.11e-06	2.25e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CA—breast cancer	1.82e-06	1.94e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—AKT1—breast cancer	1.48e-06	1.59e-05	CbGpPWpGaD
